Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Staphylococcus | 2 | 2018 | 77 | 1.41 | Why? |
| Salmonella Infections | 2 | 2018 | 82 | 1.32 | Why? |
| Bacteremia | 7 | 2018 | 1372 | 1.24 | Why? |
| Blood Culture | 2 | 2018 | 308 | 1.18 | Why? |
| Salmonella | 2 | 2018 | 58 | 0.88 | Why? |
| Staphylococcal Infections | 4 | 2018 | 1099 | 0.83 | Why? |
| Taiwan | 17 | 2021 | 2556 | 0.72 | Why? |
| Gram-Negative Bacteria | 2 | 2018 | 473 | 0.62 | Why? |
| Bacteriological Techniques | 1 | 2018 | 239 | 0.61 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2018 | 398 | 0.60 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.58 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 449 | 0.55 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 711 | 0.53 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2018 | 1115 | 0.51 | Why? |
| Diabetic Foot | 1 | 2016 | 317 | 0.47 | Why? |
| Vasculitis | 1 | 2018 | 691 | 0.43 | Why? |
| Immunoassay | 3 | 2021 | 4485 | 0.42 | Why? |
| Community-Acquired Infections | 2 | 2018 | 2328 | 0.34 | Why? |
| Anti-Bacterial Agents | 7 | 2021 | 10083 | 0.30 | Why? |
| Airway Management | 2 | 2020 | 1298 | 0.19 | Why? |
| Penicillin-Binding Proteins | 1 | 2018 | 31 | 0.18 | Why? |
| Out-of-Hospital Cardiac Arrest | 2 | 2020 | 1047 | 0.18 | Why? |
| Diverticulum | 1 | 2018 | 28 | 0.18 | Why? |
| Serologic Tests | 3 | 2021 | 4359 | 0.17 | Why? |
| Hospitals, University | 4 | 2020 | 4173 | 0.17 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.17 | Why? |
| Bone Diseases, Infectious | 1 | 2016 | 20 | 0.17 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.16 | Why? |
| Urinary Bladder | 1 | 2018 | 170 | 0.16 | Why? |
| Drug Resistance, Microbial | 1 | 2021 | 419 | 0.16 | Why? |
| Communicable Diseases | 2 | 2021 | 2148 | 0.15 | Why? |
| Serogroup | 1 | 2018 | 510 | 0.15 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.15 | Why? |
| Air Filters | 1 | 2020 | 443 | 0.14 | Why? |
| Antimicrobial Stewardship | 2 | 2021 | 931 | 0.14 | Why? |
| Random Allocation | 1 | 2017 | 773 | 0.14 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.14 | Why? |
| Mycoses | 1 | 2021 | 589 | 0.14 | Why? |
| Abscess | 1 | 2016 | 234 | 0.13 | Why? |
| Vancomycin | 1 | 2017 | 328 | 0.13 | Why? |
| Drug Synergism | 1 | 2017 | 833 | 0.13 | Why? |
| Surge Capacity | 1 | 2021 | 894 | 0.13 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.13 | Why? |
| Severe Acute Respiratory Syndrome | 7 | 2021 | 12361 | 0.12 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.12 | Why? |
| Emergency Service, Hospital | 6 | 2021 | 14232 | 0.12 | Why? |
| Microbial Sensitivity Tests | 2 | 2018 | 2886 | 0.12 | Why? |
| Sensitivity and Specificity | 5 | 2021 | 22971 | 0.12 | Why? |
| Cross Infection | 3 | 2020 | 8675 | 0.12 | Why? |
| Emergency Medical Services | 2 | 2020 | 3557 | 0.12 | Why? |
| Endocarditis, Bacterial | 1 | 2016 | 344 | 0.11 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.11 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.11 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.11 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| Aged, 80 and over | 8 | 2018 | 88759 | 0.10 | Why? |
| Aged | 13 | 2020 | 215776 | 0.10 | Why? |
| Female | 23 | 2021 | 380317 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2016 | 843 | 0.10 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.09 | Why? |
| Male | 21 | 2021 | 367725 | 0.09 | Why? |
| Methicillin | 1 | 2008 | 73 | 0.09 | Why? |
| Methicillin Resistance | 1 | 2008 | 77 | 0.09 | Why? |
| Cardiopulmonary Resuscitation | 2 | 2020 | 1876 | 0.09 | Why? |
| Adult | 17 | 2021 | 244371 | 0.08 | Why? |
| ROC Curve | 2 | 2017 | 6024 | 0.08 | Why? |
| Bacterial Infections | 1 | 2021 | 2229 | 0.08 | Why? |
| Urban Population | 1 | 2017 | 2000 | 0.08 | Why? |
| Pharynx | 2 | 2005 | 1544 | 0.08 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.08 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 2984 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Humans | 34 | 2021 | 930598 | 0.08 | Why? |
| SARS Virus | 6 | 2005 | 13021 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Risk Factors | 4 | 2018 | 71621 | 0.07 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.07 | Why? |
| Pandemics | 11 | 2021 | 389249 | 0.06 | Why? |
| Virus Diseases | 1 | 2019 | 3779 | 0.06 | Why? |
| Intubation, Intratracheal | 1 | 2017 | 3962 | 0.06 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.05 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.05 | Why? |
| Nucleocapsid | 1 | 2005 | 734 | 0.05 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.05 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.05 | Why? |
| Oxacillin | 1 | 2018 | 9 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2019 | 6817 | 0.05 | Why? |
| DNA Gyrase | 1 | 2018 | 30 | 0.05 | Why? |
| Length of Stay | 1 | 2016 | 11042 | 0.05 | Why? |
| Interleukin-8 | 1 | 2004 | 964 | 0.05 | Why? |
| Ascites | 1 | 2018 | 65 | 0.04 | Why? |
| Rupture, Spontaneous | 1 | 2018 | 115 | 0.04 | Why? |
| Intubation | 1 | 2020 | 437 | 0.04 | Why? |
| Fungi | 1 | 2021 | 471 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Ribavirin | 1 | 2004 | 1182 | 0.04 | Why? |
| Gonorrhea | 1 | 2021 | 315 | 0.04 | Why? |
| Hospitals, Isolation | 1 | 2020 | 300 | 0.04 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Drug Utilization | 1 | 2021 | 619 | 0.04 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.04 | Why? |
| Resuscitation | 1 | 2021 | 638 | 0.04 | Why? |
| Cohort Studies | 2 | 2016 | 36005 | 0.04 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Sexually Transmitted Diseases | 1 | 2021 | 694 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Fluorescent Antibody Technique | 2 | 2005 | 835 | 0.03 | Why? |
| Calcitonin Gene-Related Peptide | 1 | 2011 | 52 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2018 | 1609 | 0.03 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.03 | Why? |
| Tachycardia | 1 | 2011 | 239 | 0.02 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.02 | Why? |
| Calcitonin | 1 | 2011 | 201 | 0.02 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.02 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Equipment Design | 1 | 2020 | 3095 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Republic of Korea | 1 | 2021 | 5858 | 0.02 | Why? |
| Saliva | 1 | 2004 | 4679 | 0.02 | Why? |
| Japan | 1 | 2021 | 6653 | 0.02 | Why? |
| Protein Precursors | 1 | 2011 | 425 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.02 | Why? |
| Interleukin-6 | 1 | 2004 | 7522 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Aspartate Aminotransferases | 1 | 2011 | 1394 | 0.02 | Why? |
| Viral Load | 1 | 2004 | 15850 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| RNA, Viral | 3 | 2005 | 32276 | 0.02 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.01 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2011 | 5440 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 13720 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Masks | 1 | 2020 | 8528 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.01 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2011 | 9537 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Fever | 1 | 2011 | 7795 | 0.01 | Why? |
| Models, Statistical | 1 | 2011 | 5312 | 0.01 | Why? |
| Epithelial Cells | 1 | 2004 | 3508 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
| Antiviral Agents | 2 | 2019 | 41703 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| Communicable Diseases, Emerging | 1 | 2004 | 2523 | 0.01 | Why? |
| Antigens, Viral | 1 | 2005 | 6298 | 0.01 | Why? |
| Specimen Handling | 1 | 2004 | 6190 | 0.00 | Why? |
| Contact Tracing | 1 | 2005 | 8448 | 0.00 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2004 | 9706 | 0.00 | Why? |
| Adolescent | 1 | 2011 | 86841 | 0.00 | Why? |
Chen's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(172)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(85)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_